Leukemia Research
Volume 30, Issue 2 , Pages 222-224 , February 2006

CD34/CD117 positivity in assessment of prognosis in children with myelodysplastic syndrome

  • Betul Tavil

      Affiliations

    • Corresponding Author InformationCorresponding author at: Dumlupınar caddesi, Erzurum mahallesi, Gül sokak, No: 5/23, Ankara, Turkey. Tel.: +90 312 3051170; fax: +90 312 3112398.
    • ,
  • Mualla Çetin
    • ,
  • Murat Tuncer

Received 14 June 2005

References 

  1. Rytting ME. Pediatric myelodysplastic syndromes. Curr hematol Rep. 2004;3(3):173–177
  2. Uçkan D, Hiçsönmez G, Yetgin S, Gürgey A, Çetin M, Karaağaoğlu E, et al. CD34/CD117 co-expression in childhood acute leukemia. Leukemia Res. 2000;24:201–206
  3. Maynadie M, Picard F, Husson B, Chatelain B, Cornet Y, Roux GL, et al. GEIL Immunophenotypic clustering of myelodysplastic syndromes. Blood. 2002;100(7):2349–2356
  4. Hasle H, Baumann I, Bergstrasser E, Fenu S, Fischer A, Kardos G, et al. The International Prognostic Scoring System (IPSS) for childhood myelodysplastic syndrome (MDS) and juvenile myelomonocytic leukemia (JMML). Leukemia 2004 Oct 21 (Epub ahead of print).
  5. Hicsonmez G, Cetin M, Yenicesu I, Olcay L, Koc A, Aktas D, et al. Evaluation of children with myelodysplastic syndrome: importance of extramedullary disease as a presenting symptom. Leuk Lymphoma. 2001;42(Aug (4)):665–674
  6. Hicsonmez G, Tunc B, Olcay L, Tuncer M. Effect of short course, high-dose steroid therapy in a child with myelodysplastic syndrome. Pediatr Hematol Oncol. 2001;18(Dec (8)):525–529
  7. Stetler-Stevenson M, Arthur DC, Jabbour N, et al. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome. Blood. 2001;98:979–987
  8. Elghetany T. Diagnostic utility of flow cytometric immunophenotyping in myelodysplastic syndrome (correspondence). Blood. 2002;99:391
  9. Stetler-Stevenson M, Rick M, Arthur D. Diagnosis flow cytometric immunophenotyping in myelodysplastic syndrome: the US–Canadian consensus recommendations on the immunophenotypic analysis of hematological neoplasia by flow cytometry apply (correspondence). Blood. 2002;99:391–392
  10. Scolnik MP, Ricardo M, Bracco MM, Catovsky D, Matutes E. CD34 and CD117 are overexpressed in AML and may be valuable to detect minimal residual disease. Leukemia Res. 2002;26:615–619
  11. Wells SJ, Bray RA, Stempora LL, Farhi DC. CD117/CD34 expression in leukemic blasts. Am J Clin Pathol. 1996;106(2):192–195Aug
  12. Kiyoyuki O, Nakamura K, Yokose N, Tamura H, Tachibana M, Taniguchi O, et al. Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome. Blood. 2002;100:3887–3896
  13. Riberio E, Lima CS, Metze K, Lorand-Metze I. Flow cytometric analysis of the expression of Fas/FasI in bone marrow CD34+ cells in myelodysplastic syndromes: relation to disease progression. Leuk Lymphoma. 2004;45:309–313

PII: S0145-2126(05)00261-4

doi: 10.1016/j.leukres.2005.06.019

Leukemia Research
Volume 30, Issue 2 , Pages 222-224 , February 2006

Article Tools

* Image Usage & Resolution